Genelux
Update in progressGNLX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for aggressive solid tumors. Its lead candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus aimed at treating ovarian cancer. The company also offers the CHOICE platform and a library of engineered oncolytic VACV candidates. It has a license with Newsoara BioPharma to develop Olvi-Vec in China. Founded in 2001, based in Westlake Village, California.
Company score
- Sentiment
- 0.27
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.39
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Thomas D. Zindrick J.D.
- Founded2001
- Employees25
- Websitewww.genelux.com
Identifiers
- ISINUS36870H1032
- FIGIBBG0044BNBX6
- CUSIP36870H103
- CIK0001231457